对话独角兽 | 和铂医药的突围轨迹：以BD为矛，加速技术价值兑现

Core Insights - The Chinese pharmaceutical industry has transitioned from being associated primarily with generic drugs and raw material production to becoming a significant source of global innovative drug research and development [1][3][4] - The rise of Chinese biotech companies is reshaping the global pharmaceutical landscape, with a focus on enhancing research efficiency and cost advantages [3][4] Industry Transformation - The Chinese biotech sector is now recognized for its ability to produce approximately one-third of the global clinical pipeline of innovative drugs [3] - The shift from passive technology licensing to active global licensing has improved the international recognition of Chinese innovative drugs [3][4] Company Spotlight: Heptares Therapeutics - Heptares Therapeutics is highlighted as a leading example of a Chinese biotech firm successfully navigating the industry transformation through an effective business development (BD) strategy [1][5] - The company has achieved significant BD cooperation, with total collaboration amounts exceeding $7 billion in 2025, including partnerships with major pharmaceutical companies like AstraZeneca and Bristol-Myers Squibb [5][6] Business Development Strategy - Heptares employs a diversified BD cooperation model, including traditional licensing agreements and innovative partnerships, to enhance its pipeline value and access international markets [6] - The successful BD strategy has created a virtuous cycle of "R&D innovation—BD monetization—re-R&D," which is seen as a microcosm of the broader challenges faced by Chinese biotech firms [6] Industry Ecosystem Challenges - Despite rapid development, the Chinese biotech sector faces challenges such as funding pressures, insufficient original capabilities, and a lack of international experience [5][7] - The need for "patient capital" and support for early-stage biotech ventures is emphasized to prevent the outflow of quality companies due to funding shortages [7][8] Recommendations for Ecosystem Improvement - The Shanghai region, as a hub for biopharmaceuticals, should focus on creating a more supportive entrepreneurial environment, including funding, tax incentives, and streamlined clinical research processes [7][8] - Enhancing collaboration between academia, research institutions, and multinational corporations (MNCs) is crucial for accelerating the translation of innovations into clinical applications [8]